Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix

This article was originally published in PharmAsia News

Executive Summary

TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market

You may also be interested in...



Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)

A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources from Europe and the U.S. to Asia and seeking partnerships in those geographies. Analysts boosted earnings per share numbers to companies that disclosed detailed emerging markets sales data, such as AstraZeneca, which started the trend in Q1, and Pfizer as the first American pharma to break out emerging market sales by product. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.

New Zealand's PHARMAC Widens Access To Atorvastatin By Awarding Sole Supply Status For Generic

PERTH, Australia - Mylan's Lorstat (atorvastatin) will become New Zealand's only subsidized atorvastatin generic beginning Dec. 1. In addition, the Special Authority, which requires doctors to call in to receive authority to prescribe the drug, will be removed, reducing paperwork for prescribers and widening access to the drug

Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs

PERTH, Australia - Using sole-supply providers, New Zealand generic drug prices were considerably cheaper than corresponding drugs in Australia, Britain and Canada, according to the Pharmaceutical Management Agency's annual review for 2009

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel